Tourmaline Bio, Inc.
News
Analyzing Tourmaline Bio (NASDAQ:TRML) & Kyverna Therapeutics (NASDAQ:KYTX)
Ticker Report Tourmaline Bio (NASDAQ:TRML - Get Free Report) and Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two...\n more…
Tourmaline Bio (TRML) Receives a Buy from Piper Sandler
TipRanks Financial Blog In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Tourmaline Bio (TRML - Research Report), with a price targ...\n more…
Tourmaline Bio to Present at Upcoming Investor Conferences
Globe Newswire NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...\n more…
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $61.80 Consensus Target Price from Analysts
Zolmax Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been given an average rating of "Buy" by the six brokerages that are covering the firm, MarketBeat Ratings reports. Six equities research...\n more…
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $61.80 Average PT from Brokerages
Ticker Report Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been given an average rating of "Buy" by the six ratings firms that are covering the company, Marketbeat.com reports. Six equities research...\n more…